SHANGHAI, March 2 Shanghai will welcome Asia PharmR&D 2010 on March 4-5. This summit will converge local pharmaceuticalcompanies, hospitals, global biotech companies and research institutes andlabs in Asia, as well as those from further a field, as well as venturecapital firms and consultancies, law firms and even a translation company.Representatives in attendance include those from the U.S., Japan, mainlandChina, India and Taiwan.
The brainchild of the Global Leaders Institute (GLI) will eventually bringaround 150 delegates together with the promise of potential partneringopportunities and helpful workshops, keynote speeches, panel discussions andintriguing company showcases.
The representative from Transhorsa Translation Ltd. (supporter to thewhole translation process) describes this event as a milestone in clinicalresearch organisation ("CRO") processes in the global pharmaceutical researchchain, especially for Asia's preclinical phase. The main representatives willdeliver presentations on Asian strategies: How big pharma and biotechcompanies manage their R&D activities; How can companies derive maximum valuefrom M&A and licensing deals, diversifying product pipelines; Rethinking aboutnatural products; Exploring biologics; Pros and cons of conducting clinicaltrials in various Asian countries; How biotech companies can thrive in theprolonged funding drought; and Realizing personalized medicine throughtranslational research; Showcase of novel therapeutics for oncology,cardiology, neurology, inflammation and immunology.
Battered by economic uncertainty and under pressure to deliver bettermedical products in more cost-effective ways, pharmaceutical companies areincreasingly driven to outsource their research and development to CROs inAsia.
This trend in the biomedical sector is poised to make China one of themost popular CRO destinations within the next 10 years. This week, RightSitelooks at how investors can profit from the growth of China's CRO industry.With the rapid outsourcing development from pharmaceutical research toclinical trial, China's progress on the protection of pharmaceutical IP rightsoffers a better investment environment for multinational pharmaceuticals thatsow millions of dollars every year into R&D. The State Food and DrugAdministration (SFDA) Law of China was revised in 2000 to allow the patentingof pharmaceutical compositions, which established a major improvement over theprevious practice of only allowing the patenting of a method to make or use adrug.
According to research published by Australian law firm DLA Phillips Fox,China has put new measures in place to raise the penalties for patentinfringement from 300% to 400% of illicit profits and increasing damagepayments from RMB 50,000 to RMB 200,000, even if there is no profit from theinfringement. These changes are just part of the changing attitudes towardsprotecting patents and other intellectual property that is making China moreattractive for research dependent industries such as CROs.
"China's returnees abundant human capital, lower business costs andexperienced returnees (nicknamed "seaturtles" in China) is allowingentrepreneurs to build Chinese biotech firms that are far more integrated --with significant capabilities in disciplines ranging from discovery researchthrough clinical development -- than their counterparts in the west. And thisintegrated approach can produce more efficient and productive R&D," describedSamantha Du, Ph.D. Chief Executive Officer, Hutchison MediPharma Limited.
Trends in pharmaceutical development is an area organizations are mostconcerned with, and Greg Wiederrech PhD, Vice President & Head from Merck &Co., will present Driving Innovation through Strategic Relationships at theSummit, "Pipeline woes throughout the pharma industry are well acknowledgedand executives are responding via a number of strategic actions includingmergers, acquisitions, entries into other modalities such as biologics andsiRNA, entries into new geographic markets, regional deal making, and morerisk sharing. Some of these strategies will win and some may not."
Chunlin Chen PhD of Shanghai Medicilon Inc, said, "Many CROs emerged inChina to offer customers cost-effective synthetic capabilities as well as aidwith molecular design and preclinical services. Currently, more and moreinternational and domestic pharmaceutical companies are seeking integratedservices CROs for their R&D work." He will state different collaborationpatterns between integrated services CROs and pharmaceutical companies that hehas assumed with many case studies in practice and ahead of the development.
Regarding the current financial downturn, Fintan Walton PhD, ChiefExecutive and Founder, PharmaVentures UK appears to have a positive outlook as"pharma companies, biotech and startups, when looking to China and Asia toconduct R&D more efficiently, tap into local centres of expertise, and optionsfor funding in the region are becoming increasingly diverse against a backdropof a global biotech funding downturn" like OBN's press release statement"Biotech Investment is Safer than Banks."
The summit will make a successful round of presentations and a largenumber of private partnering discussions occurring throughout the two days,GLI will push pharmaceutical and preclinical research far more than everbefore.
At the heart of the financial and business district in Shanghai, thebeautiful InterContinental Hotels & Resorts will be the base for this summit,and private business meetings and one-on-one networking sessions are going toensure Asia Pharm R&D 2010 can create a more efficient and effective way forcontributors of this field to communicate and improve their projects tosuccess.For more information, please contact: Monica Sun Tel: +86-10-5900-0971 x607 Email: Monica.firstname.lastname@example.org
SOURCE Global Leaders Institute